NUCB2 and metabolic disease: Consequently, WAT increases the amount of proinflammatory adipokines (such as visfatin and chemerin) and decreases the concentration of anti-inflammatory adipokines (nesfatin-1, neuregulin 4), contributing to a low-grade inflammatory state and the progression of obesity-linked metabolic disorders like impaired immune response and greater risk of infectious diseases [8,10,11,12].